Leah Kuntz

A new study examined the relationship between ADHD and oppositional defiant and conduct disorder, callous-unemotional traits, and reward-related inhibitory control.

Treatment-resistant depression: how to diagnose, what treatment options are available, and how to best help patients.

The FDA has approved Dyanavel XR, extended release once-daily tablets for the treatment of attention-deficit/hyperactivity disorder.

How can you provide affirmative mental health care for transgender and gender diverse patients?

Benzodiazepines: a class of medications that evokes that a visceral reaction.

Here’s how to integrate treatment strategies that address both ADHD and comorbid conditions.

Did you miss the Annual Psychiatric Times World CME Conference? Don't worry, we've got you covered.

Can mindfulness be an additional therapy to help treat ADHD in children?

Three leading groups in child and adolescent mental health have declared a state of emergency for the nation’s youth.

One man shares his suicide survival story, and what he does to aid suicide prevention.

Nearly 80% of eating disorders go undetected. What screening tools can help identify them?

PH94B for the treatment of social anxiety disorder further differentiates its mechanism of action from benzodiazepines in a new lab rat preclinical study.

Cultural differences between patients and physician are hard to avoid. How can you best work with diverse patients?

Transgender youth are at increased risk for a number of psychiatric morbidities. Gender identity conversion therapy can make them worse.

Phase 3 results on MDMA-assisted therapy look promising for the treatment of PTSD. What other disorders can psychedelics help treat?

Chronic adolescent exposure to THC and cannabis could lead to adverse mental health outcomes and impacted brain functioning.

Bringing science to the practice of psychiatry has been the personal goal of Sheldon H. Preskorn, MD—the Educator of the Year.

Psychiatric Times' Editor in Chief shared some insights and data on the psychiatric impacts of COVID-19, and what we might expect in the future.

Modifications to the Clozapine Risk Evaluation and Mitigation Strategy go into effect November 15, 2021. Are you up to date?

Caplyta shows promise as a monotherapy for patients with bipolar I or bipolar II disorder experiencing a major depressive episode

The Chief Medical Officer for the American Foundation for Suicide Prevention sat down to talk with Psychiatric Times about a number of important topics in suicide.

According to German researchers, YouTube and other online platforms could induce a “mass social media-induced illness.”

The American Medical Association is urging policymakers to act now to prevent further opioid overdose deaths.

A vaccine that prevents oxycodone from entering the brain? This might be the safe, long-lasting, cost-effective solution for opioid use disorders.

A recent survey found 70% of Afghanistan veterans have struggled with their mental health since serving.

The FDA is holding a workshop to discuss mandatory opioid prescriber education through the Opioid Analgesic Risk Evaluation and Mitigation Strategy.

The first and only treatment to use proprietary precision olfactory delivery technology to deliver DHE to the upper nasal cavity just received FDA approval.

6 frontline physician groups expressed their concern about the Texas state law that bans abortions after 6 weeks of pregnancy.

The one-of-its-kind 6-month paliperidone palmitate treatment for schizophrenia has received FDA approval.

According to the CDC, construction workers commit suicide 4 times more than the general population. What can be done to stem this hazard?